edaravone has been researched along with Hypoxia-Ischemia, Brain in 19 studies
Hypoxia-Ischemia, Brain: A disorder characterized by a reduction of oxygen in the blood combined with reduced blood flow (ISCHEMIA) to the brain from a localized obstruction of a cerebral artery or from systemic hypoperfusion. Prolonged hypoxia-ischemia is associated with ISCHEMIC ATTACK, TRANSIENT; BRAIN INFARCTION; BRAIN EDEMA; COMA; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 7.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| "Edaravone, a potent antioxidant, may improve thrombolytic therapy because it benefits ischemic stroke patients on its own and mitigates adverse effects of tissue plasminogen activator (tPA) in preclinical models." | 3.80 | Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. ( Abe, K; Chan, PH; Dunn, RS; Kuan, CY; Li, Y; Lindquist, DM; Morozov, YM; Rakic, P; Sun, YY; Yang, D, 2014) |
| "Pretreatment with edaravone can prevent development of cognitive impairment after CEA." | 2.71 | Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy. ( Endo, H; Fukuda, T; Inoue, T; Kobayashi, M; Ogasawara, K; Ogawa, A; Terasaki, K; Yamadate, K; Yoshida, K, 2005) |
| "Edaravone is a new type of oxygen free radical scavenger and able to attenuate various brain damage including hypoxic-ischemic brain damage (HIBD)." | 1.48 | Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. ( Fu, R; Huang, Y; Lei, J; Li, C; Li, H; Luo, S; Mo, Z; Zhang, L, 2018) |
| "Edaravone or saline was prophylactically applied to compare their effects on cortical oxygen saturation, blood flow, coagulation, oxidative stress, metabolites, and learning-memory using methods that include photoacoustic imaging, laser speckle contrast imaging, solid-state NMR, and Morris water maze." | 1.42 | Prophylactic Edaravone Prevents Transient Hypoxic-Ischemic Brain Injury: Implications for Perioperative Neuroprotection. ( Abe, K; Heinmiller, A; Kuan, CY; Lee, J; Li, Y; Mao, H; Sayeed, I; Stein, DG; Sun, YY; Wali, B, 2015) |
| "Edaravone is a brain-penetrant free radical scavenger that is known to ameliorate postischemic neuronal dysfunction." | 1.37 | Edaravone and carnosic acid synergistically enhance the expression of nerve growth factor in human astrocytes under hypoxia/reoxygenation. ( Hayakari, R; Imaizumi, T; Ishikawa, A; Itoh, K; Kosaka, K; Matsumiya, T; Metoki, N; Mimura, J; Ota, K; Satoh, K; Tanji, K; Yoshida, H, 2011) |
| "Edaravone may inhibit the number of apoptotic neuronal cells and 8-OHdG expression within 48 h after HI insult." | 1.35 | Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat. ( Goto, Y; Itoh, M; Miyazawa, T; Nonoyama, S; Takizawa, Y, 2009) |
| "Edaravone was administered intraperitoneally (9 mg/kg) after hypoxic-ischemic insult every 24 hours for 2, 5, or 10 consecutive days." | 1.33 | Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. ( Aoo, N; Egashira, N; Fujiwara, M; Ikeda, T; Ikenoue, T; Iwasaki, K; Mishima, K; Noor, JI; Ohta, S, 2005) |
| "Edaravone has an inhibitory effect on lipid peroxidation by scavenging free radicals and prevents vascular endothelial cell injury." | 1.32 | Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats. ( Ishida, A; Nakajima, W; Takada, G; Yasuoka, N, 2004) |
| " Seven-day-old rat pups were subjected to a modified Levine procedure, then given either vehicle or MCI-186 (at one of three dosage levels: 3, 6, or 9 mg/kg), and the extent of brain damage was evaluated either 24 h or 7 days later." | 1.31 | Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats. ( Ikeda, T; Ikenoue, T; Kaneko, M; Sameshima, H; Xia, YX, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Yamato, SH | 1 |
| Nakamura, S | 1 |
| Htun, Y | 1 |
| Nakamura, M | 1 |
| Jinnai, W | 1 |
| Nakao, Y | 1 |
| Mitsuie, T | 1 |
| Koyano, K | 1 |
| Wakabayashi, T | 1 |
| Morimoto, AH | 1 |
| Sugino, M | 1 |
| Iwase, T | 1 |
| Kondo, SI | 1 |
| Yasuda, S | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Kusaka, T | 1 |
| Youssef, MI | 1 |
| Ma, J | 1 |
| Chen, Z | 1 |
| Hu, WW | 1 |
| Li, C | 1 |
| Mo, Z | 1 |
| Lei, J | 1 |
| Li, H | 1 |
| Fu, R | 1 |
| Huang, Y | 1 |
| Luo, S | 1 |
| Zhang, L | 1 |
| Sun, YY | 2 |
| Morozov, YM | 1 |
| Yang, D | 1 |
| Li, Y | 3 |
| Dunn, RS | 1 |
| Rakic, P | 1 |
| Chan, PH | 1 |
| Abe, K | 2 |
| Lindquist, DM | 1 |
| Kuan, CY | 2 |
| Wali, B | 1 |
| Lee, J | 1 |
| Heinmiller, A | 1 |
| Stein, DG | 1 |
| Mao, H | 1 |
| Sayeed, I | 1 |
| Takizawa, Y | 1 |
| Miyazawa, T | 1 |
| Nonoyama, S | 1 |
| Goto, Y | 1 |
| Itoh, M | 1 |
| Shimizu, M | 1 |
| Watanabe, M | 1 |
| Masaoka, N | 1 |
| Nakajima, Y | 1 |
| Nagaishi, M | 1 |
| Yamamoto, T | 1 |
| Kojima, T | 1 |
| Ueda, Y | 4 |
| Adati, N | 1 |
| Kitamoto, A | 1 |
| Sato, A | 1 |
| Huang, MC | 1 |
| Noor, J | 1 |
| Sameshima, H | 2 |
| Ikenoue, T | 6 |
| Yoshida, H | 1 |
| Mimura, J | 1 |
| Imaizumi, T | 1 |
| Matsumiya, T | 1 |
| Ishikawa, A | 1 |
| Metoki, N | 1 |
| Tanji, K | 1 |
| Ota, K | 1 |
| Hayakari, R | 1 |
| Kosaka, K | 1 |
| Itoh, K | 1 |
| Satoh, K | 1 |
| Ni, X | 1 |
| Yang, ZJ | 1 |
| Carter, EL | 1 |
| Martin, LJ | 1 |
| Koehler, RC | 1 |
| Ikeda, T | 5 |
| Xia, YX | 1 |
| Kaneko, M | 1 |
| Yasuoka, N | 1 |
| Nakajima, W | 1 |
| Ishida, A | 1 |
| Takada, G | 1 |
| Yokoyama, H | 1 |
| Itoh, O | 1 |
| Noor, JI | 4 |
| Ogasawara, K | 1 |
| Yamadate, K | 1 |
| Kobayashi, M | 1 |
| Endo, H | 1 |
| Fukuda, T | 1 |
| Yoshida, K | 1 |
| Terasaki, K | 1 |
| Inoue, T | 1 |
| Ogawa, A | 1 |
| Mishima, K | 1 |
| Aoo, N | 1 |
| Ohta, S | 1 |
| Egashira, N | 1 |
| Iwasaki, K | 1 |
| Fujiwara, M | 1 |
| Zhu, C | 1 |
| Wang, X | 1 |
| Huang, Z | 1 |
| Qiu, L | 1 |
| Xu, F | 1 |
| Vahsen, N | 1 |
| Nilsson, M | 1 |
| Eriksson, PS | 1 |
| Hagberg, H | 1 |
| Culmsee, C | 1 |
| Plesnila, N | 1 |
| Kroemer, G | 1 |
| Blomgren, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury[NCT03968042] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for edaravone and Hypoxia-Ischemia, Brain
| Article | Year |
|---|---|
Potential therapeutic agents for ischemic white matter damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Disease Models, Animal; Edaravone; H | 2021 |
[Topics of the brain protection in neonate, which has been your better choice, the brain hypothermia or the medicine?].
Topics: Allopurinol; Antioxidants; Antipyrine; Edaravone; Erythropoietin; Free Radical Scavengers; Free Radi | 2009 |
1 trial available for edaravone and Hypoxia-Ischemia, Brain
| Article | Year |
|---|---|
Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy.
Topics: Aged; Antipyrine; Carotid Artery, Internal; Carotid Stenosis; Cerebral Infarction; Cerebrovascular C | 2005 |
16 other studies available for edaravone and Hypoxia-Ischemia, Brain
| Article | Year |
|---|---|
Intravenous Edaravone plus Therapeutic Hypothermia Offers Limited Neuroprotection in the Hypoxic-Ischaemic Newborn Piglet.
Topics: Animals; Animals, Newborn; Brain; Disease Models, Animal; Edaravone; Hypothermia, Induced; Hypoxia; | 2020 |
Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway.
Topics: Animals; Animals, Newborn; Apoptosis; Cognitive Dysfunction; Disease Models, Animal; Edaravone; Gene | 2018 |
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
Topics: Animals; Antipyrine; Cell Hypoxia; Disease Models, Animal; Drug Synergism; Edaravone; Humans; Hypoxi | 2014 |
Prophylactic Edaravone Prevents Transient Hypoxic-Ischemic Brain Injury: Implications for Perioperative Neuroprotection.
Topics: Animals; Antipyrine; Edaravone; Free Radical Scavengers; Hypoxia-Ischemia, Brain; Male; Mice; Mice, | 2015 |
Edaravone inhibits DNA peroxidation and neuronal cell death in neonatal hypoxic-ischemic encephalopathy model rat.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Animals, Newborn; Antipyrine; Cell Death; Deoxyguanosine; Dise | 2009 |
Changes of expression of glucose transporters in the fetal lamb brain after MCI-186 administration to the maternal circulation with 10-min persistent umbilical cord occlusion.
Topics: Animals; Antipyrine; Arterial Occlusive Diseases; Brain; Drug Evaluation, Preclinical; Edaravone; Fe | 2009 |
Gene network analysis to determine the effects of antioxidant treatment in a rat model of neonatal hypoxic-ischemic encephalopathy.
Topics: Animals; Animals, Newborn; Antioxidants; Antipyrine; Disease Models, Animal; Edaravone; Female; Free | 2010 |
Edaravone and carnosic acid synergistically enhance the expression of nerve growth factor in human astrocytes under hypoxia/reoxygenation.
Topics: Abietanes; Antioxidants; Antipyrine; Astrocytes; Cell Survival; Cells, Cultured; Drug Synergism; Eda | 2011 |
Striatal neuroprotection from neonatal hypoxia-ischemia in piglets by antioxidant treatment with EUK-134 or edaravone.
Topics: Animals; Animals, Newborn; Antioxidants; Antipyrine; Corpus Striatum; Edaravone; Free Radical Scaven | 2011 |
Effect of the free radical scavenger, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), on hypoxia-ischemia-induced brain injury in neonatal rats.
Topics: Animals; Animals, Newborn; Antipyrine; Brain; Edaravone; Female; Free Radical Scavengers; Hypoxia-Is | 2002 |
Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats.
Topics: Animals; Animals, Newborn; Antipyrine; Blotting, Western; Brain; Caspase 3; Caspases; Cell Count; Ce | 2004 |
EPR imaging to estimate the in vivo intracerebral reducing ability of mature rats after neonatal hypoxic-ischemic brain injury.
Topics: Animals; Animals, Newborn; Antipyrine; Blood-Brain Barrier; Brain; Carotid Artery, Common; Cyclic N- | 2004 |
Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy.
Topics: Animals; Animals, Newborn; Antipyrine; Behavior, Animal; Brain; Brain Ischemia; Drug Administration | 2005 |
A free radical scavenger, edaravone, inhibits lipid peroxidation and the production of nitric oxide in hypoxic-ischemic brain damage of neonatal rats.
Topics: Animals; Animals, Newborn; Antipyrine; Brain Chemistry; Edaravone; Hypoxia-Ischemia, Brain; Lipid Pe | 2005 |
Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia.
Topics: Amino Acid Chloromethyl Ketones; Animals; Animals, Newborn; Antipyrine; Apoptosis; Apoptosis Inducin | 2007 |
Edaravone inhibits lipid peroxidation in neonatal hypoxic-ischemic rats: an in vivo microdialysis study.
Topics: Animals; Animals, Newborn; Antipyrine; Dose-Response Relationship, Drug; Edaravone; Electron Spin Re | 2007 |